Ribupatide

瑞普泊肽

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameRibupatide
Drug Alias NameHRS9531HRS-9531KAI-9531
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightWeight LossBody Weight +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[4] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesFujian Suncadia Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesKailera Therapeutics IncHercules CM NewCoFujian Suncadia Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightWeight LossBody Weight +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A